Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies
- PMID: 9727629
- DOI: 10.1046/j.1525-1500.1998.00055.x
Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies
Abstract
Monoclonal antibody (MoAb) 2C5, a nucleosome-specific antinuclear autoantibody (ANA) from the repertoire of aged mice, was recently reported to recognize the surface of various tumor cells but not normal cells. Surface-bound nucleosomes (NSs) were previously proven to be MoAb 2C5's target on the outer membrane of tumor cells. Furthermore, MoAb 2C5 was found to have a strong antitumor effect during the early stages of tumor development. In an attempt to further increase antitumor effect of nucleosome-specific tumorocidal monoclonal antibody against established tumors, we investigated a possible way to enhance antibody association with tumor cells. Evidence is presented here demonstrating that the in vitro treatment of tumor cells (S49 T lymphoma) resulting in a partial cell death and massive liberation of intact NSs from dead tumor cells into the culture medium was accompanied by a 50-fold increase of MoAb 2C5 binding to the surface of surviving tumor cells. Massive NS release was observed in the case of S49 T-cell treatment with dexamethasone and vincristine. However, a partial cell killing that was not accompanied with NS release (EL4 lymphoma treatment with doxorubicin) did not result in the enhanced binding of MoAb 2C5 to the surface of surviving tumor cells. The use of NS-specific tumorocidal antibodies, such as MoAb 2C5, in combination with another NS release-inducing tumor therapy, should provide an enhanced antibody-tumor binding.
Similar articles
-
A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice.Oncol Res. 1997;9(8):439-46. Oncol Res. 1997. PMID: 9436197
-
Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents.Ther Deliv. 2010 Aug;1(2):257-72. doi: 10.4155/tde.10.30. Ther Deliv. 2010. PMID: 22816132 Review.
-
Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.J Liposome Res. 2007;17(1):1-14. doi: 10.1080/08982100601186474. J Liposome Res. 2007. PMID: 17454399
-
Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.J Control Release. 2004 Nov 5;100(1):135-44. doi: 10.1016/j.jconrel.2004.08.007. J Control Release. 2004. PMID: 15491817
-
Autoimmunity against nucleosomes and lupus nephritis.Ann Med Interne (Paris). 1996;147(7):485-9. Ann Med Interne (Paris). 1996. PMID: 9092359 Review.
Cited by
-
Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.Drug Deliv Transl Res. 2024 Aug;14(8):2171-2185. doi: 10.1007/s13346-024-01562-5. Epub 2024 Mar 20. Drug Deliv Transl Res. 2024. PMID: 38507033 Free PMC article.
-
Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.Res Sq [Preprint]. 2023 Dec 11:rs.3.rs-3713164. doi: 10.21203/rs.3.rs-3713164/v1. Res Sq. 2023. Update in: Drug Deliv Transl Res. 2024 Aug;14(8):2171-2185. doi: 10.1007/s13346-024-01562-5. PMID: 38168301 Free PMC article. Updated. Preprint.
-
Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers.Pharmaceutics. 2022 Jul 15;14(7):1470. doi: 10.3390/pharmaceutics14071470. Pharmaceutics. 2022. PMID: 35890364 Free PMC article.
-
Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.Pharm Res. 2021 Mar;38(3):429-450. doi: 10.1007/s11095-021-02986-1. Epub 2021 Mar 2. Pharm Res. 2021. PMID: 33655395
-
In vivo histone H1 migration from necrotic to viable tissue.Oncotarget. 2017 Mar 7;8(10):16275-16292. doi: 10.18632/oncotarget.15181. Oncotarget. 2017. PMID: 28187445 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous